Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients

[1]  R. Pastorello,et al.  Gastric Pouch Mixed Adenoneuroendocrine Carcinoma With a Mixed Adenocarcinoma Component After Roux-en-Y Gastric Bypass , 2017, Journal of investigative medicine high impact case reports.

[2]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[3]  T. Morikawa,et al.  Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma , 2017, Neuroendocrinology.

[4]  Chang-ming Huang,et al.  Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach , 2017, Oncotarget.

[5]  R. Hua,et al.  Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas , 2017, World journal of gastroenterology.

[6]  C. Zheng,et al.  Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  Y. Jeng,et al.  High neuroendocrine component is a factor for poor prognosis in gastrointestinal high‐grade malignant mixed adenoneuroendocrine neoplasms , 2015, Journal of the Chinese Medical Association : JCMA.

[8]  J. Soares,et al.  Gastric Mixed Adenoneuroendocrine Carcinoma , 2015, GE: Portuguese Journal of Gastroenterology.

[9]  Y. Ajioka,et al.  Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis , 2014, Gastric Cancer.

[10]  H. Tsuda,et al.  Neuroendocrine Carcinoma of the Stomach: Morphologic and Immunohistochemical Characteristics and Prognosis , 2013, The American journal of surgical pathology.

[11]  M. Choi,et al.  Changes in Postoperative Recurrence and Prognostic Risk Factors for Patients with Gastric Cancer who Underwent Curative Gastric Resection during Different Time Periods , 2013, Annals of Surgical Oncology.

[12]  T. Luong,et al.  Gastric Mixed Adenoneuroendocrine Carcinoma with a Trilineage Cell Differentiation: Case Report and Review of the Literature , 2012, Case Reports in Oncology.

[13]  S. Knappskog,et al.  Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy , 2011, Cancer.

[14]  A. Vanoli,et al.  Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. , 2011, Human pathology.

[15]  Hyundong Chae,et al.  Composite Neuroendocrine Carcinoma with Adenocarcinoma of the Stomach Misdiagnosed as a Giant Submucosal Tumor , 2011, Journal of gastric cancer.

[16]  Ken Kato,et al.  Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma , 2011, Gastric Cancer.

[17]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  I. Modlin,et al.  Carcinoid tumors of the stomach. , 2003, Surgical oncology.

[19]  G. Pelosi,et al.  Microallelotyping Defines the Monoclonal or the Polyclonal Origin of Mixed and Collision Endocrine-Exocrine Tumors of the Gut , 2003, Laboratory Investigation.

[20]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[21]  Japanese Gastric Cancer Association.  Japanese Classification of Gastric Carcinoma – 2nd English Edition – , 1998 .

[22]  K. Lewin.  Carcinoid tumors and the mixed (composite) glandular-endocrine cell carcinomas. , 1987, The American journal of surgical pathology.